Theranos at a Crossroad: What's Next for the Startup?

The transcript discusses the challenges faced by Theranos, focusing on Sunny Balwani's controversial role, board member changes, and ongoing regulatory investigations. It highlights the company's lack of medical expertise and the need for data transparency. The future steps for Theranos include addressing compliance issues and providing substantial data to regain credibility.

What was a major criticism of Theranos regarding its executive team?

• Lack of legal expertise

• Lack of marketing expertise

• Lack of medical expertise

• Lack of financial expertise

What significant change occurred in the Theranos board recently?

• They added a new marketing executive

• They removed all previous board members

• They reappointed previous board members and added a former Amgen executive

• They dissolved the board entirely

What is one of the main challenges Theranos is currently facing?

• Regulatory investigations

• Lack of funding

• Employee strikes

• Product recalls

What is Theranos expected to do by August 1st to address its challenges?

• Hire a new CEO

• Publish substantial data and get their lab in compliance

• Launch a new product

• Expand to international markets

What has Elizabeth Holmes failed to provide in response to criticism?

• A public apology

• A new product line

• A new business strategy

• Evidence that the technology works